Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm, phase-II trial

This phase-II study (ClinicalTrials.gov identifier: NCT03052478) aimed to evaluate the efficacy and safety of vismodegib, an inhibitor targeting the Hedgehog signaling pathway, in patients with refractory advanced gastric cancer. Patients with refractory advanced gastric cancer, whose disease had pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ryul, Ji, Jun Ho, Kim, Jung Hoon, Hong, Jung Yong, Lim, Ho-Yeong, Kang, Won Ki, Lee, Jeeyun, Kim, Seung Tae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899372/
https://www.ncbi.nlm.nih.gov/pubmed/35281856
http://dx.doi.org/10.7150/jca.67050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899372/
https://www.ncbi.nlm.nih.gov/pubmed/35281856
http://dx.doi.org/10.7150/jca.67050

Ejemplares similares